![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Zoledronic acid is the only bisphosphonate approved for the prevention or delay of skeletal-related events in patients with bone metastases secondary to prostate cancer. Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer. This article summarizes the cost–effectiveness literature pertaining to these two agents when used in the prevention of skeletal-related events secondary to malignancy. Zoledronic acid (and denosumab in comparison with zoledronic acid) have been found to be cost effective and cost ineffective depending on the analytical perspective and model parameters.
Financial & competing interests disclosure
JA Carter and MF Botteman received a consulting fee related to the development of this manuscript from Novartis Pharmaceuticals Corporation, which is the manufacturer of zoledronic acid. Novartis Pharmaceuticals Corporation was not involved in the planning or execution of this review. Pharmerit, the research and consulting group for which JA Carter is a research analyst and MF Botteman is managing partner, has received consulting fees from Amgen (maker of denosumab), but has received no consulting fees associated with denosumab-related projects or projects related to the subject matter herein per Expert Review guidelines regarding drug profiles, a Novartis employee checked the completed manuscript for scientific and medical accuracy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.